Moderna, Inc. (MRNA)
Moderna, Merck say vaccine improved survival in patients with deadly skin cancer
Moderna and Merck said their experimental vaccine in combination with the therapy Keytruda improved survival and showed durable efficacy in a midstage study in patients with a deadly form of skin cancer. Nearly 75% of patients who took the combination were alive without any signs or symptoms of their cancer returning at the 2½-year mark.
Moderna-Merck skin cancer vaccine shows survival benefit in long-term follow-up
Moderna and partner Merck & Co said on Monday their cancer vaccine in combination with blockbuster cancer therapy Keytruda improved survival and showed durable efficacy in a mid-stage study in patients with a deadly form of skin cancer.
Is Moderna Stock a Buy Now That It's a 2-Product Company?
Moderna earned approval for mResvia, a respiratory syncytial virus vaccine, on May 31. Instead of soaring in response to the great news, Moderna stock fell.
Moderna secures a second FDA vaccine approval as Spikevax sales plummet
Moderna announced on Friday that the U.S. Food and Drug Administration (FDA) has approved its respiratory syncytial virus (RSV) vaccine for adults ages 60 and older. This will be the only RSV vaccine available in single-dose prefilled syringes and will be sold under the brand name mRESVIA.
Moderna Investors Just Got Some Bullish News
Moderna has brought in billions of dollars in earnings thanks to its coronavirus vaccine. But demand for that product has declined, and that has worried investors.
Moderna, Inc. (MRNA) Bernstein's 40th Annual Strategic Decisions Conference (Transcript)
Moderna, Inc. (NASDAQ:MRNA ) Bernstein's 40th Annual Strategic Decisions Conference May 31, 2024 10:00 PM ET Company Participants Stephane Bancel - CEO Conference Call Participants Courtney Breen - Bernstein Courtney Breen Hi, there, everyone. It's great to see you all on Friday of the conference.
Moderna wins second product approval with RSV vaccine
Moderna Inc.'s respiratory syncytial virus vaccine for older adults received U.S. regulatory approval, the company said Friday, marking the first time a messenger RNA vaccine has been approved for a disease other than COVID-19.
Moderna Wins FDA Approval For Second-Ever Product; Why Its RSV Vaccine Could Dominate Pfizer, GSK
The FDA approved Moderna's RSV vaccine, allowing the biotech to launch its second-ever product. But Moderna stock retreated.
FDA approves Moderna's RSV vaccine for seniors, the company's second-ever product
The Food and Drug Administration approved Moderna's vaccine for respiratory syncytial virus. The decision is a win for Moderna, which desperately needs another revenue source amid plunging demand for its Covid jab, its only commercially available product.
US FDA approves Moderna's RSV vaccine, its second marketed product
The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.
Why Moderna Stock Is Sinking This Week
Investors appear to be taking profits after Moderna stock soared last week. The big moves center around concerns about the H5N1 avian flu, also known as bird flu.
Moderna Pops After Confirming The U.S. Government Could Back Its Bird Flu Vaccine
Moderna stock jumped early Thursday after confirming the U.S. government is nearing a deal to fund its pandemic bird flu vaccine.
